Cipla Limited — Q2FY27 earnings call summary

Filed 30 October 2026 · Official transcript

North America revenue $172M, targeting $1B exit run rate FY27 with 3 major launches pending
EBITDA margin guidance maintained at 18.5-20% for FY27
R&D spend at 5.7% of revenue this quarter; full year guidance 6-7%
One India business grew 12% Y-o-Y with strong chronic portfolio growth; launches in respiratory, antidiabetes, cardiovascular
Multiple analyst queries on US ramp-up; management confident on achieving $1B run rate via existing and new product launches
Domestic branded prescription business outperformed market with 15% growth; consumer health showing steady growth
Q2FY27 revenue INR7,404 Cr, +4% Q-o-Q; EBITDA margin 18.7%, +200 bps Q-o-Q
Biosimilars pipeline advancing; partnership with Qilu for Pembrolizumab in North America